Cartesian Therapeutics, Inc.
RNAC
$6.36
-$0.30-4.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.80M | 1.09M | 1.03M | 34.17M | 38.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.80M | 1.09M | 1.03M | 34.17M | 38.91M |
| Cost of Revenue | 58.03M | 54.65M | 52.25M | 50.04M | 44.91M |
| Gross Profit | -55.24M | -53.56M | -51.22M | -15.87M | -5.99M |
| SG&A Expenses | 31.47M | 30.36M | 29.20M | 28.99M | 29.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.50M | 85.01M | 81.45M | 79.03M | 74.43M |
| Operating Income | -86.71M | -83.92M | -80.43M | -44.86M | -35.52M |
| Income Before Tax | -139.50M | -47.69M | -35.97M | -38.02M | -77.14M |
| Income Tax Expenses | -9.19M | 287.00K | 287.00K | 287.00K | 287.00K |
| Earnings from Continuing Operations | -130.30 | -47.98 | -36.26 | -38.31 | -77.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.30M | -47.98M | -36.26M | -38.31M | -77.42M |
| EBIT | -86.71M | -83.92M | -80.43M | -44.86M | -35.52M |
| EBITDA | -83.75M | -81.08M | -77.91M | -42.74M | -34.37M |
| EPS Basic | -5.01 | -1.86 | -1.60 | -1.54 | -10.67 |
| Normalized Basic EPS | -1.84 | -1.79 | -1.59 | -0.70 | -2.20 |
| EPS Diluted | -5.03 | -1.87 | -1.61 | -1.57 | -10.71 |
| Normalized Diluted EPS | -1.83 | -1.78 | -1.59 | -0.73 | -2.22 |
| Average Basic Shares Outstanding | 103.89M | 103.31M | 98.78M | 89.52M | 69.03M |
| Average Diluted Shares Outstanding | 104.36M | 103.78M | 99.24M | 90.59M | 70.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |